Verona Pharma plc
VRNA
$63.32
-$2.94-4.44%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -158.50% | -218.96% | -203.27% | -142.89% | -4.64% |
| Total Depreciation and Amortization | 39.21% | 56.28% | 62.42% | 44.05% | 24.29% |
| Total Amortization of Deferred Charges | 888.89% | 1,094.83% | 376.50% | 147.50% | 147.50% |
| Total Other Non-Cash Items | 384.53% | 215.95% | 144.95% | 231.35% | 5.64% |
| Change in Net Operating Assets | -245.24% | 58.72% | 168.52% | 185.09% | -62.12% |
| Cash from Operations | -106.98% | -143.33% | -118.19% | -1.73% | -13.53% |
| Capital Expenditure | -6,768.75% | -- | -- | -- | 44.83% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -6,768.75% | -- | -- | -- | 44.83% |
| Total Debt Issued | 753.30% | 216.47% | 656.21% | 656.21% | 43.59% |
| Total Debt Repaid | -- | -- | -793.26% | -793.26% | -- |
| Issuance of Common Stock | 10,755.57% | 74.83% | -92.51% | -99.59% | -99.53% |
| Repurchase of Common Stock | -1,425.92% | -229.65% | -578.30% | -200.40% | -110.25% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 24,953.46% | 775,808.33% | 47,586.22% | 1,099.03% | 96.15% |
| Cash from Financing | 1,169.45% | 170.04% | 152.74% | -11.03% | -89.98% |
| Foreign Exchange rate Adjustments | -9.53% | -100.85% | 5.82% | -101.00% | 213.19% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 501.10% | 191.24% | 206.54% | -15.92% | -123.03% |